Impact of Polatuzumab vedotin as first-line therapy for DLBCL on subsequent treatments - Brazilian model

Samir Nabhan¹, Douglas Castro², Veronica E. Mata²

1. Hospital de Clínicas de Curitiba - Universidade do Paraná, Curitiba, Brazil, 2. F. Hoffmann-La Roche Ltd, São Paulo, Brazil.





References:

1. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma: a paradigm shift? Blood. 2022 May 5;139(18):2737-2746. doi: 10.1182/blood.2022015789. Erratum in: Blood. 2023 Feb 09;141(6):683. doi: 10.1182/blood.2022018793. 3. Roche Brasil. Expert panel led by Origin do Brasil; 4. Tilly H, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 386:351-363; 5. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165; 6. Bartlett NL, et al. Polatuzumab Vedotin in R Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019; 28:4184-4190. J; 8. Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with a the rituximab era. J Clin Oncol. 2010; 28:4184-4190. J; 8. Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest. 2006 Oct; 24(6):593-600. doi: 10.1080/07357900600814490; 9. Crump M, Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethas Locke F et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):640-654; 11. Neelapu, s. et al. Axicabtagene Ciloleucel in patients with relapsed or refractory aggressive B-cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):640-654; 11. Neelapu, s. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory aggressive B-cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):640-654; 11. Neelapu, s. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory aggressive B-cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544; 12. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):640-654; 11. Neelapu, s. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory aggressive B-cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544; 12. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544; 12. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell Aggressive B-cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544; 12. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell Aggressive B-c lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct; 22(10): 1403-1415. doi: 10.1016/S1470-2045(21)00375-2; 13. Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul; 21(7): 978-988; 14. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul; 21(7): 978-988; 14. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul; 21(7): 978-988; 14. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul; 21(7): 978-988; 14. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul; 21(7): 978-988; 14. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul; 21(7): 978-988; 14. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul; 21(7): 978-988; 14. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or refractory diffuse or Refractory Diffuse Large B-Cell Lymphoma: J Clin Oncol. 2020 Jan 10;38(2):155-165; 15. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725; 16. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy: a phase II Lymphoma Study Association trial. Haematologica 2013;98:1726-1731.

Quantitative analysis based on an expert panel discussion about a sequence of treatments model in DLBCL analyzed using a decision tree (figure 1) $^{1-3}$.

All DLBCL patients treated with Pola-R-CHP as 1L vs. patients treated with R-CHOP (scenario A); and DLBCL patients (ABC diagnosis) treated with Pola-R-CHP as 1L vs. patients treated with R-CHOP

• The model uses 2-year disease progression rate and market share of the different treatments based on clinical evidence and expert panel opinions, respectively (Table 1) $^{4-16}$.

RESULTS

- One hundred patients initiated the sequence of treatment. • For scenario A the number of patients that progressed using R-CHOP to 2L is 30. After 2L treatments, 24 progressed to 3L and 19 to 4L. When these patients were treated with Pola-R-CHP in 1L, 23
- progressed to 2L, 19 to 3L and 15 to 4L (Table 2) • For scenario B, 41 patients progressed after using R-CHOP as a 1L, 34 progressed to 3L and 27 to 4L.

(Table 3)).			

Table 2. Number of patients progressing in scenario A.

itment line	Scenario A (all DLBCL)		Treatment line	Scenario B (ABC DLBCL)	
	R-CHOP	Pola-R-CHP		R-CHOP	Pola-R-CI
1°	100	100	1°	100	100
2°	30	23	2°	41	16
3°	24	19	3°	34	13
4°	19	15	4°	27	10

CONCLUSION

and resource allocation.

• This model demonstrates the impact of treatment with Pola-R-CHP in 1L in terms of the number of patients with progression-free survival and the possibility of a cure, as well as the reduced necessity for other lines of treatment that have lower efficacy and may have higher costs. • This information could help decision makers engage in discussions based on evidence and value for patients and healthcare systems, promoting more efficiency and visibility in terms of budget impact

29.8% 41.2% 23.3% 16.1% 54.0% 60.0% 50.0% 50.0%

2-year

50.0%	
47.0%*	
62.0%	
54.0%	
71.6%	
72.2%	
87.0%	



EE205

On the other hand, 16 patients progressed to 2L after using Pola-R-CHP in 1L, 13 to 3L, and 10 to 4L

Table 3. Number of patients progressing in scenario B.